GINI, Beatrice
 Distribuzione geografica
Continente #
NA - Nord America 761
EU - Europa 484
AS - Asia 212
AF - Africa 2
Continente sconosciuto - Info sul continente non disponibili 1
SA - Sud America 1
Totale 1.461
Nazione #
US - Stati Uniti d'America 761
CN - Cina 168
GB - Regno Unito 159
SE - Svezia 66
FR - Francia 53
IE - Irlanda 53
FI - Finlandia 49
IT - Italia 40
DE - Germania 27
SG - Singapore 18
KR - Corea 15
RU - Federazione Russa 14
UA - Ucraina 11
BE - Belgio 7
IR - Iran 6
BD - Bangladesh 2
TR - Turchia 2
AL - Albania 1
AT - Austria 1
CH - Svizzera 1
CL - Cile 1
EG - Egitto 1
EU - Europa 1
ID - Indonesia 1
PL - Polonia 1
RS - Serbia 1
SC - Seychelles 1
Totale 1.461
Città #
Chandler 191
Southend 145
Woodbridge 102
Jacksonville 95
Houston 61
Dublin 53
Ann Arbor 52
Beijing 36
Ashburn 25
Wilmington 23
Verona 22
Jinan 21
Lawrence 21
Princeton 21
Nanjing 16
Seoul 15
New York 14
Shenyang 12
Hebei 10
Singapore 10
Brussels 7
Redwood City 7
Tianjin 7
Hangzhou 6
Helsinki 6
Jiaxing 6
Mashhad 6
Milan 6
Ningbo 6
Falls Church 5
Florence 5
Haikou 5
Taizhou 5
Zhengzhou 5
Cagliari 4
Guangzhou 4
Lancaster 4
Changsha 3
Freyming-Merlebach 3
Oakland 3
Taiyuan 3
Boardman 2
Dongguan 2
Edinburgh 2
Fuzhou 2
Hayward 2
Nanchang 2
Norwalk 2
San Diego 2
San Francisco 2
Seattle 2
Secaucus 2
Belgrade 1
Bilgi 1
Bonndorf 1
Boston 1
Cairo 1
Columbus 1
Como 1
Dearborn 1
Düsseldorf 1
Fairfield 1
Gelsenkirchen 1
Jakarta 1
Jeffries 1
Lappeenranta 1
Las Vegas 1
Oklahoma City 1
Polska 1
Puxian 1
Redmond 1
Reno 1
Shenzhen 1
Sindelfingen 1
Stanford 1
Tappahannock 1
Tomsk 1
Vienna 1
Washington 1
Yicheng 1
Zurich 1
Totale 1.102
Nome #
Adipose-derived mesenchymal stem cells ameliorate chronic experimental autoimmune encephalomyelitis. 108
2D immunomic approach for the study of IgG autoantibodies in the experimental model of multiple sclerosis. 94
A proteomic approach to identify autoantigens in Hashimoto's encephalopathy [Un approccio proteomico per l'identificazione di autoantigeni nell'encefalopatia di Hashimoto] 93
Preventive and therapeutic beneficial effect of adipose-derived mesenchymal stem cells in chronic EAE 89
The mTOR kinase inhibitors, CC214-1 and CC214-2, preferentially block the growth of EGFRvIII-activated glioblastomas. 89
BIOMOLECULAR TECHNOLOGIES IN THE STUDY OF CENTRAL NERVOUS SYSTEM DISEASES 78
Novel autoantigens recognized by CSF IgG from Hashimoto's encephalitis revealed by a proteomic approach 75
Transketolase and 2',3'-cyclic-nucleotide 3'-phosphodiesterase type I isoforms are specifically recognized by IgG autoantibodies in multiple sclerosis patients. 73
Recombinant inbred systems can advance research in behavioral ecology. 70
EGFR mutation-induced alternative splicing of Max contributes to growth of glycolytic tumors in brain cancer. 70
Different content of chitin-like polysaccharides in multiple sclerosis and Alzheimer's disease brains 66
Hashimoto encephalopathy and antibodies against dimethylargininase-1: a rare cause of cognitive decline in a pediatric Down's syndrome patient. 65
Greater than the sum of its parts: single-nucleus sequencing identifies convergent evolution of independent EGFR mutants in GBM. 63
Single-cell phosphoproteomics resolves adaptive signaling dynamics and informs targeted combination therapy in glioblastoma 61
Oncogenic EGFR signaling activates an mTORC2-NF-κB pathway that promotes chemotherapy resistance. 60
A tale of two approaches: complementary mechanisms of cytotoxic and targeted therapy resistance may inform next-generation cancer treatments. 58
Longitudinal evaluation of MPIO-labeled stem cell biodistribution in glioblastoma using high resolution and contrast-enhanced MR imaging at 14.1 tesla. 57
mTOR complex 2 controls glycolytic metabolism in glioblastoma through FoxO acetylation and upregulation of c-Myc. 55
Targeted therapy resistance mediated by dynamic regulation of extrachromosomal mutant EGFR DNA. 53
An LXR agonist promotes glioblastoma cell death through inhibition of an EGFR/AKT/SREBP-1/LDLR-dependent pathway. 53
PML mediates glioblastoma resistance to mammalian target of rapamycin (mTOR)-targeted therapies. 50
Totale 1.480
Categoria #
all - tutte 4.872
article - articoli 4.392
book - libri 0
conference - conferenze 246
curatela - curatele 0
other - altro 234
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 9.744


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2019/2020153 21 0 1 9 7 33 23 8 5 12 21 13
2020/2021157 11 34 21 15 29 17 2 9 5 0 13 1
2021/2022167 11 65 0 13 3 7 4 6 7 7 12 32
2022/2023436 25 60 25 69 51 106 0 28 57 4 9 2
2023/2024162 6 13 12 6 11 40 5 23 4 15 19 8
2024/202513 13 0 0 0 0 0 0 0 0 0 0 0
Totale 1.480